Compounds > daunorubicin
Page last updated: 2024-08-23

daunorubicin and AIDS-Related Opportunistic Infections

daunorubicin has been researched along with AIDS-Related Opportunistic Infections in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boag, F; Bower, M; Gazzard, BG; Hannon, F; Money-Kyrle, J; Muyshondt, C; Phillips, R; Uthayakumar, S; Youle, M1
Dupont, B; Eliaszewicz, M; Feuillie, V; Fournier, S; Gonzalez-Canali, G; Pialoux, G1
White, RM1
Goebel, FD; Jablonowski, H1
Careddu, A; D'Incalci, M; Fumagalli, L; Lazzarin, A; Parisi, I; Viganò, MG; Zecca, B; Zucchetti, M1

Trials

4 trial(s) available for daunorubicin and AIDS-Related Opportunistic Infections

ArticleYear
Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma.
    AIDS (London, England), 1996, Volume: 10, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Cross-Over Studies; Daunorubicin; Drug Carriers; Humans; Liposomes; Male; Sarcoma, Kaposi

1996
Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
    Archives of dermatology, 1997, Volume: 133, Issue:7

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; CD4 Lymphocyte Count; Daunorubicin; Digestive System Neoplasms; Disease Progression; Drug Carriers; Humans; Liposomes; Lung Neoplasms; Remission Induction; Sarcoma, Kaposi; Skin Neoplasms; Survival Rate

1997
Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
    European journal of medical research, 1999, Dec-16, Volume: 4, Issue:12

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Antiviral Agents; Cost-Benefit Analysis; Daunorubicin; Doxorubicin; Hepatitis C, Chronic; Herpesvirus 8, Human; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Ribavirin; Sarcoma, Kaposi

1999
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:6

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antineoplastic; Daunorubicin; Drug Interactions; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Indinavir; Liposomes; Male; Middle Aged; Ritonavir; Saquinavir; Sarcoma, Kaposi

2000

Other Studies

2 other study(ies) available for daunorubicin and AIDS-Related Opportunistic Infections

ArticleYear
Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
    AIDS (London, England), 1997, Volume: 11, Issue:11

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Clinical Trials as Topic; Cross-Over Studies; Daunorubicin; Drug Carriers; HIV Infections; Humans; Immunocompromised Host; Liposomes; Sarcoma, Kaposi

1997
Paclitaxel for treating KS.
    Project Inform perspective, 1997, Issue:23

    Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Carriers; Humans; Liposomes; Paclitaxel; Sarcoma, Kaposi

1997